1. 2007
2. Cyhoeddwyd

   Quantitative risk-benefit analysis

   Hughes, D. & Hughes, D. A., 1 Mai 2007.

   Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

3. Cyhoeddwyd

   What determines which interventions improve compliance, and do they improve health outcomes in a cost-effective manner?

   Hughes, D., Hughes, D. A., LaFleur.*, N. V., Salas, M. & Shinogle, J., 1 Mai 2007.

   Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

4. Cyhoeddwyd

   Adherence with HAART: pharmacoeconomic considerations

   Hughes, D. & Hughes, D. A., 1 Meh 2007.

   Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

5. Cyhoeddwyd

   Adverse drug reactions in economic evaluations

   Hughes, D. & Hughes, D. A., 1 Gorff 2007.

   Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

6. Cyhoeddwyd

   A prototype agent-based model of antimalarial drug compliance

   Hughes, D., McKean, J., Rahlf, S., Shorter, H., Barnish, G., Paton, R., McBurney, P., Hughes, D. A. & Hastings, I., 1 Awst 2007.

   Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

7. Cyhoeddwyd

   Cost of non-compliance and non-persistence with medications for diabetes mellitus

   Hughes, D., Salas, M., Hughes, D. A., Lebmeier, M. & Vardeva, K., 1 Awst 2007.

   Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

8. Cyhoeddwyd

   Current assessment of risk-benefit by regulators: Is it time to introduce decision analyses?

   Hughes, D., Hughes, D. A., Pirmohamed, M. & Bayoumi, A., 1 Awst 2007.

   Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

9. Cyhoeddwyd

   Current assessment of risk-benefit by regulators: is it time to introduce decision analyses?

   Hughes, D., Hughes, D. A., Bayoumi, A. M. & Pirmohamed, M., 1 Awst 2007, Yn: Clinical Pharmacology and Therapeutics. 82, 2, t. 123-127

   Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

10. Cyhoeddwyd

    Impact of the abolition of prescription charges in Wales: a multi-level modelling approach with application to time series dispensed rate data

    Hughes, D., Alam, F., Myles, S., Hughes, D. A., Dunstan, F., Routledge, P. & Cohen, D., 1 Medi 2007.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

11. Cyhoeddwyd

    Feasibility, validity and reliability of the Welsh version of the EQ-5D health status questionnaire.

    Hughes, D. & Hughes, D. A., 1 Hyd 2007, Yn: Quality of Life Research. 16, 8, t. 1419-1423

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

12. Cyhoeddwyd

    Interventions that enhance medication compliance and persistence: Theoretical grounding, and economic assessment

    Hughes, D., Hughes, D. A., Gwadry Sridhar, F., Elliott, R. & Cowell, W., 1 Hyd 2007.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

13. Cyhoeddwyd

    Pharmacoeconomic evaluations in Ireland, Scotland and Wales: A Celtic perspective on pharmaceutical assessment

    Hughes, D., Hughes, D. A., Drummond, M., Tolley, K. & Ryan, M., 1 Hyd 2007.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

14. Cyhoeddwyd

    The assessment, determinants & economics of medication compliance & persistence

    Hughes, D., Hughes, D. A., Gwadry Sridhar, F. & Elliott, R., 1 Hyd 2007.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

15. Cyhoeddwyd

    Methods for integrating medication compliance and persistence in pharmacoeconomic evaluations.

    Hughes, D., Hughes, D. A., Cowell, W., Koncz, T. & Cramer, J., 1 Tach 2007, Yn: Value in Health. 10, 6, t. 498-509

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

16. Cyhoeddwyd

    Orphan drug treatments: economic considerations

    Hughes, D. & Hughes, D. A., 1 Tach 2007.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

17. Cyhoeddwyd

    Population pharmacokinetics of warfarin: Intermin analysis of the Liverpool pharmacogenetic prospective cohort study

    Hughes, D., Matthews, I., Aarons, L., Al-Zubiedi, S., Hatch, E., Lane, S., Williamson, P., Kamali, F., Hughes, D. A. & Pirmohamed, M., 1 Tach 2007.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

18. Cyhoeddwyd

    The effect of compliance upon clinical effectiveness of chlorproguanil-dapsone (CD) and artemether-lumefantrine (AL) when compared to sulfadoxine-pyrimethamine (SP) for the treatment of uncomplicated falcipaum malaria in Malawi - a randomised controlled trial

    Hughes, D., Bell, D. J., Wootton, D., Mukaka, M., Montgomery, J., Kayange, N., Chimpeni, P., Zijlstra, E., Hughes D.A., N. V., Molyneux M.E.*, N. V., Ward, S. A., Winstanley, P. A. & Lalloo, D. G., 1 Tach 2007.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

19. Cyhoeddwyd

    Folate Augmentation of Treatment – Evaluation for Depression (FolATED): protocol of a randomised controlled trial.

    Russell, I. T., Slegg, G. P., Roberts, S. H., Bedson, E., Hughes, D., Lloyd, K., Moat, S., Pirmohamed, M., Slegg, G., Tranter, R., Whitaker, R., Wilkinson, C. & Russell, I., 15 Tach 2007, Yn: BMC Psychiatry. 7, 1, t. 65

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

20. Cyhoeddwyd

    A Global Survey of Antibiotic Leftovers in the Outpatient Setting.

    Hughes, D., Kardas, P., Pechere, J. C., Hughes, D. A. & Cornaglia, G., 1 Rhag 2007, Yn: International Journal of Antimicrobial Agents. 30, 6, t. 530-536

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

21. Cyhoeddwyd

    Public meetings of the NICE appraisals committee

    Hughes, D. & Hughes, D. A., 1 Rhag 2007.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

22. Cyhoeddwyd

    The pharmacokinetic profile of Warfarn: a systematic review

    Hughes, D., Al-Zubiedi S.*, N. V., Hughes D.A., N. V. & Pirmohamed, M., 1 Rhag 2007.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

23. 2008
24. Cyhoeddwyd

    All Wales Medicines Strategy Group Final Appraisal Report - Abacavir 600mg/lamivudine 300mg (Kivexa) in antiretroviral combination therapy for the treatment of Human Immunodeficiency Virus infection in adults and adolescents from 12 years of age.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2008, 2008 gol. Unknown.

    Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

25. Cyhoeddwyd

    All Wales Medicines Strategy Group Final Appraisal Report - Alemtuzumab (MabCampath) for the treatment of patients with B-cell chronic lymphocytic leukaemia for whom fludarabine combination chemotherapy is not appropriate.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2008, 2008 gol. Unknown.

    Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

26. Cyhoeddwyd

    All Wales Medicines Strategy Group Final Appraisal Report - Atazanavir (Reyataz) in treatment-experienced patients.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2008, 2008 gol. Unknown.

    Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

27. Cyhoeddwyd

    All Wales Medicines Strategy Group Final Appraisal Report - Atazanavir (Reyataz) in treatment-naïve patients.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2008, 2008 gol. Unknown.

    Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn